414 related articles for article (PubMed ID: 9317196)
1. Determinants of fetal hemoglobin response to hydroxyurea.
Steinberg MH
Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
3. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
[TBL] [Abstract][Full Text] [Related]
4. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
Vicari P; Barretto de Mello A; Figueiredo MS
Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
[TBL] [Abstract][Full Text] [Related]
5. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
6. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea.
Ma Q; Wyszynski DF; Farrell JJ; Kutlar A; Farrer LA; Baldwin CT; Steinberg MH
Pharmacogenomics J; 2007 Dec; 7(6):386-94. PubMed ID: 17299377
[TBL] [Abstract][Full Text] [Related]
7. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
Steinberg MH; Lu ZH; Barton FB; Terrin ML; Charache S; Dover GJ
Blood; 1997 Feb; 89(3):1078-88. PubMed ID: 9028341
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
Rodgers GP
Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
[TBL] [Abstract][Full Text] [Related]
9. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
10. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea in children: present and future.
Vichinsky EP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium.
Haynes J; Obiako B; Hester RB; Baliga BS; Stevens T
Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H379-85. PubMed ID: 17993595
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
15. [Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].
de Montalembert M
Pathol Biol (Paris); 1999 Jan; 47(1):55-8. PubMed ID: 10081780
[TBL] [Abstract][Full Text] [Related]
16. Fetal hemoglobin and F-cell responses to long-term hydroxyurea treatment in young sickle cell patients. The French Study Group on Sickle Cell Disease.
Maier-Redelsperger M; de Montalembert M; Flahault A; Neonato MG; Ducrocq R; Masson MP; Girot R; Elion J
Blood; 1998 Jun; 91(12):4472-9. PubMed ID: 9616141
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells.
Brun M; Bourdoulous S; Couraud PO; Elion J; Krishnamoorthy R; Lapoumeroulie C
Pharmacogenomics J; 2003; 3(4):215-26. PubMed ID: 12931135
[TBL] [Abstract][Full Text] [Related]
18. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
20. Localisation of cis regulatory elements at the beta-globin locus: analysis of hybrid haplotype chromosomes.
Ofori-Acquah SF; Lalloz MR; Layton DM
Biochem Biophys Res Commun; 1999 Jan; 254(1):181-7. PubMed ID: 9920754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]